Ralliant (NYSE:RAL) Updates Q2 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.580-0.640 for the period, compared to the consensus earnings per share estimate of 0.520. The company issued revenue guidance of $540.0 million-$556.0 million, compared to the consensus revenue estimate of $529.0 million. Ralliant also updated its FY 2026 guidance to 2.530-2.690 EPS.

Ralliant Trading Up 4.5%

NYSE RAL opened at $49.36 on Tuesday. The firm has a market capitalization of $5.52 billion and a P/E ratio of 25.18. The business has a fifty day simple moving average of $44.32 and a 200 day simple moving average of $47.07. Ralliant has a 12 month low of $37.27 and a 12 month high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter. The company had revenue of $534.60 million during the quarter. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts predict that Ralliant will post 2.37 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is presently 10.20%.

Analyst Ratings Changes

RAL has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Oppenheimer decreased their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. Truist Financial decreased their target price on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Royal Bank Of Canada decreased their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 6th. Finally, Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $50.50.

Insider Buying and Selling

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total value of $246,825.00. Following the completion of the transaction, the senior vice president owned 46,756 shares in the company, valued at $2,104,020. This trade represents a 10.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RAL. Palisade Asset Management LLC bought a new position in Ralliant in the 3rd quarter worth about $26,000. BOKF NA bought a new position in Ralliant in the 3rd quarter worth about $29,000. Wilmington Savings Fund Society FSB bought a new position in Ralliant in the 3rd quarter worth about $30,000. EverSource Wealth Advisors LLC bought a new position in Ralliant in the 2nd quarter worth about $39,000. Finally, NewEdge Advisors LLC bought a new position in Ralliant in the 2nd quarter worth about $43,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.